Aging https://www.bioworld.com/rss en-us With $80M series D, Life Biosciences advances epigenetic reprogramming http://www.bioworld.com/articles/730208 Thu, 09 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/730208-with-80m-series-d-life-biosciences-advances-epigenetic-reprogramming Illustration of double helix Topical ASO restores WRN function for chronic skin ulcers in Werner syndrome C mutation.]]> http://www.bioworld.com/articles/730187 Wed, 08 Apr 2026 09:00:00 -0400 https://www.bioworld.com/articles/730187-topical-aso-restores-wrn-function-for-chronic-skin-ulcers-in-werner-syndrome Missing puzzle piece and broken DNA chain Five-drug VIPOR regimen shows promise in aggressive blood cancer http://www.bioworld.com/articles/730204 Tue, 07 Apr 2026 11:00:00 -0400 https://www.bioworld.com/articles/730204-five-drug-vipor-regimen-shows-promise-in-aggressive-blood-cancer PET scans showing before and after treatment with VIPOR Before (top) and after (bottom) treatment with VIPOR. Full-body and cross-sectional PET scans of a patient show large lymphoma tumors (circled in red) that have disappeared with treatment. Credit: Center for Cancer Research/National Cancer Institute Five-drug VIPOR regimen shows promise in aggressive blood cancer http://www.bioworld.com/articles/729980 Wed, 01 Apr 2026 12:00:00 -0400 https://www.bioworld.com/articles/729980-five-drug-vipor-regimen-shows-promise-in-aggressive-blood-cancer PET scans showing before and after treatment with VIPOR Before (top) and after (bottom) treatment with VIPOR. Full-body and cross-sectional PET scans of a patient show large lymphoma tumors (circled in red) that have disappeared with treatment. Credit: Center for Cancer Research/National Cancer Institute Braveheart finds phase II positive for cardiac myosin inhibitor http://www.bioworld.com/articles/729968 Tue, 31 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729968-braveheart-finds-phase-ii-positive-for-cardiac-myosin-inhibitor 3D illustration of heart cross section Small-molecule TREM2 agonist advances to treat Alzheimer’s http://www.bioworld.com/articles/730054 Fri, 27 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/730054-small-molecule-trem2-agonist-advances-to-treat-alzheimers Comparison of neurons in a healthy brain and nerve cells in neurodegenerative disease with amyloid plaques Small-molecule TREM2 agonist advances to treat Alzheimer’s http://www.bioworld.com/articles/729927 Thu, 26 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729927-small-molecule-trem2-agonist-advances-to-treat-alzheimers Comparison of neurons in a healthy brain and nerve cells in neurodegenerative disease with amyloid plaques Emerging therapeutic strategies for Parkinson’s at ADPD 2026 http://www.bioworld.com/articles/729789 Mon, 23 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729789-emerging-therapeutic-strategies-for-parkinsons-at-adpd-2026 Art concept for Parkinson's disease ADPD 2026: Three inflection points to target Alzheimer’s disease http://www.bioworld.com/articles/729852 Fri, 20 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729852-adpd-2026-three-inflection-points-to-target-alzheimers-disease Illustration of Alzheimer's disease in the brain ADPD 2026: Three inflection points to target Alzheimer’s disease http://www.bioworld.com/articles/729719 Thu, 19 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729719-adpd-2026-three-inflection-points-to-target-alzheimers-disease Illustration of Alzheimer's disease in the brain ADPD 2026: Can we prevent dementia? Scientists quantify it http://www.bioworld.com/articles/729688 Wed, 18 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729688-adpd-2026-can-we-prevent-dementia-scientists-quantify-it MRI image brain on black background Kanaph, Imbiologics to kick off 2026 Korea biotech, med-tech IPOs http://www.bioworld.com/articles/729714 Tue, 17 Mar 2026 11:00:00 -0400 https://www.bioworld.com/articles/729714-kanaph-imbiologics-to-kick-off-2026-korea-biotech-med-tech-ipos Ha Gyong sik giving a presentation Ha Gyong-sik, CEO, Imbiologics Kanaph, Imbiologics to kick off 2026 Korea biotech, med-tech IPOs http://www.bioworld.com/articles/729495 Fri, 13 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729495-kanaph-imbiologics-to-kick-off-2026-korea-biotech-med-tech-ipos Ha Gyong sik giving a presentation Ha Gyong-sik, CEO, Imbiologics Korean ARPA-H to invest ₩162B in nine projects in 2026 http://www.bioworld.com/articles/729582 Tue, 10 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729582-korean-arpa-h-to-invest-162b-in-nine-projects-in-2026 Korea ARPA-H roundtable K-health MIRAE Initiative Director General Sun Kyung, center, and project managers at a roundtable meeting in Seoul, South Korea on March 5. Taiwan to invest $752M in biopharma security over four years http://www.bioworld.com/articles/729579 Tue, 10 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729579-taiwan-to-invest-752m-in-biopharma-security-over-four-years Taiwan President Lai Ching-te presides over the seventh meeting of the Healthy Taiwan Promotion Committee. Taiwan President Lai Ching-te, center, presides over the seventh meeting of the Healthy Taiwan Promotion Committee. Synthetic peptide and CAR-A each clear amyloid-β in Alzheimer’s http://www.bioworld.com/articles/729577 Tue, 10 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729577-synthetic-peptide-and-car-a-each-clear-amyloid-in-alzheimers Illustration of amyloid plaques on neurons Taiwan to invest $752M in biopharma security over four years http://www.bioworld.com/articles/729440 Mon, 09 Mar 2026 12:00:00 -0400 https://www.bioworld.com/articles/729440-taiwan-to-invest-752m-in-biopharma-security-over-four-years Taiwan President Lai Ching-te presides over the seventh meeting of the Healthy Taiwan Promotion Committee. Taiwan President Lai Ching-te, center, presides over the seventh meeting of the Healthy Taiwan Promotion Committee. Synthetic peptide and CAR-A each clear amyloid-β in Alzheimer’s http://www.bioworld.com/articles/729411 Mon, 09 Mar 2026 09:00:00 -0400 https://www.bioworld.com/articles/729411-synthetic-peptide-and-car-a-each-clear-amyloid-in-alzheimers Illustration of amyloid plaques on neurons Korean ARPA-H to invest ₩162B in nine projects in 2026 http://www.bioworld.com/articles/729359 Fri, 06 Mar 2026 12:00:00 -0500 https://www.bioworld.com/articles/729359-korean-arpa-h-to-invest-162b-in-nine-projects-in-2026 Korea ARPA-H roundtable K-health MIRAE Initiative Director General Sun Kyung, center, and project managers at a roundtable meeting in Seoul, South Korea on March 5. CROI 2026 highlights depression and cognitive vulnerability in HIV http://www.bioworld.com/articles/729051 Thu, 26 Feb 2026 08:00:00 -0500 https://www.bioworld.com/articles/729051-croi-2026-highlights-depression-and-cognitive-vulnerability-in-hiv Depression concept with human, broken brain and heavy rain CROI 2026: Neurodegeneration, the challenge of aging with HIV http://www.bioworld.com/articles/729031 Wed, 25 Feb 2026 08:00:00 -0500 https://www.bioworld.com/articles/729031-croi-2026-neurodegeneration-the-challenge-of-aging-with-hiv Brain and virus with chromosome Innovacell’s $91M Tokyo IPO to fund incontinence cell therapies http://www.bioworld.com/articles/729194 Tue, 24 Feb 2026 12:00:00 -0500 https://www.bioworld.com/articles/729194-innovacells-91m-tokyo-ipo-to-fund-incontinence-cell-therapies Glass yen/yuan symbol Japan endorses two iPSC drugs for approval under CEA pathway http://www.bioworld.com/articles/729235 Tue, 24 Feb 2026 11:00:00 -0500 https://www.bioworld.com/articles/729235-japan-endorses-two-ipsc-drugs-for-approval-under-cea-pathway Stem cells Japan endorses two iPSC drugs for approval under CEA pathway http://www.bioworld.com/articles/729099 Fri, 20 Feb 2026 12:00:00 -0500 https://www.bioworld.com/articles/729099-japan-endorses-two-ipsc-drugs-for-approval-under-cea-pathway Stem cells A closer look at how the liver rejuvenates the aging brain http://www.bioworld.com/articles/728933 Thu, 19 Feb 2026 08:00:00 -0500 https://www.bioworld.com/articles/728933-a-closer-look-at-how-the-liver-rejuvenates-the-aging-brain Mouse on treadwheel AI transforming med tech in 2026; clinical need drives investments http://www.bioworld.com/articles/729072 Wed, 18 Feb 2026 12:00:00 -0500 https://www.bioworld.com/articles/729072-ai-transforming-med-tech-in-2026-clinical-need-drives-investments AI medical illustration T cells store lipids and die in rheumatoid arthritis joints http://www.bioworld.com/articles/728915 Wed, 18 Feb 2026 11:00:00 -0500 https://www.bioworld.com/articles/728915-t-cells-store-lipids-and-die-in-rheumatoid-arthritis-joints X-ray image of hand and wrist SCAN is core circuit affected in Parkinson’s disease http://www.bioworld.com/articles/729173 Wed, 18 Feb 2026 08:00:00 -0500 https://www.bioworld.com/articles/729173-scan-is-core-circuit-affected-in-parkinsons-disease Illustration of SCAN in Parkinson’s vs healthy subcortex The brain network that links thinking with movement, called SCAN, has been identified in a new study as the neurological basis of Parkinson’s disease. An experimental therapy that targeted this network more than doubled symptom improvement in a small group of patients with Parkinson’s, which is characterized by hyperconnectivity (left side of illustration) between SCAN and the brain’s subcortex. Credit: Sara Moser, WashU Medicine. Heart intervention device-maker Insight lands $143M SSE IPO http://www.bioworld.com/articles/728803 Tue, 10 Feb 2026 11:00:00 -0500 https://www.bioworld.com/articles/728803-heart-intervention-device-maker-insight-lands-143m-sse-ipo Insight Lifetech IPO ceremony Insight Lifetech bell-ringing ceremony at the Shanghai Stock Exchange Feb. 5, 2026. Credit: Insight Lifetech Co. Ltd. Heart intervention device-maker Insight lands $143M SSE IPO http://www.bioworld.com/articles/728662 Fri, 06 Feb 2026 12:00:00 -0500 https://www.bioworld.com/articles/728662-heart-intervention-device-maker-insight-lands-143m-sse-ipo Insight Lifetech IPO ceremony Insight Lifetech bell-ringing ceremony at the Shanghai Stock Exchange Feb. 5, 2026. Credit: Insight Lifetech Co. Ltd.